Author/Authors :
Shafaghi، Behrouz نويسنده , , Jarollahi، Ali نويسنده Pars Hospital Laboratory , , Yousefzadeh، Bahman نويسنده Pars Hospital Laboratory , , Ameri، Ahmad نويسنده Department of Radiation Oncology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences , , Nasiraei-Moghadam، Shiva نويسنده Department of Biology, Faculty of Basic Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran , , Mostafavi، Mostafa نويسنده ,
Abstract :
Human papilloma virus prevalence data is scarce in Iran. This study was performed to evaluate
type-specific human papilloma virus prevalence and to compare it with Pap smear results among Iranian
women attending regular gynecological visits.
Patients and methods: A total of 851 women aged 18-65 years, attending regular gynecological visits
were retrospectively evaluated. Human papilloma virus detection and genotyping was performed using
polymerase chain reaction technique. Cytological evaluation was performed by Papanicolaou method and
the association between cytological results and human papilloma virus profile was analyzed.
Results: Nineteen different types of human papilloma virus were detected in 265 of 851 patients (31.1%).
Overall infection as well as infection with high risk human papilloma virus types; were highest in women
aged 18-25 years and decreased with age. Type-specific prevalence of human papilloma virus -16 and 18
was 7.3% and 2.8% respectively. There was also an upward trend in the prevalence of high risk human
papilloma virus infection as the abnormality in cytology increased. The prevalence of human papilloma
virus related events was 29.1% among virus positive patients and declined from low grade squamous
intraepithelial lesion (18.2%) to high grade squamous intraepithelial lesion (3.9%).
Conclusion: Our study indicated that the burden of human papilloma virus infection among Iranian females
was higher in comparison with previous estimates reported from Iran. Furthermore, higher prevalence of
premalignant changes in Iranian women infected with high risk human papilloma virus types other than
vaccine types should be considered in immunization programs and development of population-specific
human papilloma virus vaccines.